TheraRadar
← Back
Data updated: Jun 28, 2026

Gilead Sciences

GILD Biotech
Infectious DiseaseOncologyImmunology Execution: Good

Antiviral specialist with dominant HIV franchise (Biktarvy, Descovy) and hepatitis C cures. Expanding into oncology through acquisitions.

$28.4B
Revenue (2024)
$115.0B
Market Cap
-
Trials
4
New Drugs (2yr)
Modality:
20 Small Molecules 2 Biologics

FDA Novel Drug Designations

(2016-2024)
6 Novel 2 First-in-Class 2 Orphan 4 Breakthrough 1 Accelerated 6 Priority Review 3 Fast Track
See 6 novel approvals →
2024 LIVDELZI (SELADELPAR LYSINE) Orphan · Breakthrough · Priority Review · Accelerated
2022 SUNLENCA (LENACAPAVIR SODIUM) First-in-Class · Orphan · Breakthrough · Priority Review · Fast Track
2020 VEKLURY (REMDESIVIR) First-in-Class · Priority Review · Fast Track
2018 BIKTARVY (BICTEGRAVIR SODIUM) Priority Review
2017 VOSEVI (SOFOSBUVIR) Breakthrough · Priority Review
2016 EPCLUSA (SOFOSBUVIR) Breakthrough · Priority Review · Fast Track

Gilead Sciences at a Glance

  • Leading 27 drug targets across portfolio
  • Fast trial execution (23 months median completion)

Upcoming FDA Decisions

Full Calendar →
Aug 27, 2026 — bictegravir and lenacapavir (BIC LEN)

Gilead Sciences's Key Drugs

Gilead Sciences's core commercial portfolio centers on BIKTARVY, DESCOVY, GENVOYA, spanning Infectious Disease and Oncology — its most strategically important drugs approved in the last 15 years.

BIKTARVY
Infectious Disease

Human Immunodeficiency Virus

Approved 2018
DESCOVY
Infectious Disease

HIV-1 Infection

Approved 2016
GENVOYA
Infectious Disease

HIV-1 Infection

CYP3A Approved 2015
Yescarta
CD19 Approved 2017
VEMLIDY
Infectious Disease

Hepatitis B

Approved 2016

Gilead Sciences's Recent FDA Approvals

Gilead Sciences secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

HEPCLUDEX BLA
2026-05-22
bulevirtide-gmod
1 INDICATIONS AND USAGE HEPCLUDEX is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. This indication is approved under accelerated approval based on a decrease in HDV RNA and alanine aminotransferase (ALT) normalization [see Clinical Studies (14) ] . An improvement in disease-related clinical outcomes has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). HEPCLUDEX is a sodium taurocholate co-transporting polypeptide (NTCP)-directed HDV attachment inhibitor indicated for the treatment of chronic HDV infection in adults without cirrhosis or with compensated cirrhosis. This indication is approved under accelerated approval based on participants who achieved a decrease in HDV RNA and alanine aminotransferase (ALT) normalization. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 , 14 )
YEZTUGO NDA
2025-06-18
lenacapavir sodium
HIV
YEZTUGO NDA
2025-06-18
lenacapavir
HIV
LIVDELZI NDA
2024-08-14
seladelpar lysine
Primary Biliary Cholangitis

Gilead Sciences's Therapeutic Areas

Gilead Sciences's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Oncology, across 2 biologic and 20 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 61%
16 drugs Phase 3: 102 Phase 2: 115 Phase 1: 49
Oncology 22%
1 drugs Phase 3: 30 Phase 2: 41 Phase 1: 70
Immunology 9%
2 drugs Phase 3: 16 Phase 2: 16 Phase 1: 11
Respiratory 6%
2 drugs Phase 3: 9 Phase 2: 7 Phase 1: 9
Cardiovascular 3%
1 drugs Phase 3: 3 Phase 2: 8 Phase 1: 4

Gilead Sciences Pipeline Snapshot

Gilead Sciences has 490 active clinical programs from ClinicalTrials.gov — 160 Phase 3, 187 Phase 2 and 143 Phase 1.

160
Phase 3
187
Phase 2
143
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2026
Sacituzumab Govitecan-hziy
Metastatic Breast Cancer
Estimated · fresh NCT04639986
Q1 2027
Sacituzumab Govitecan-hziy
Triple Negative Breast Cancer
Estimated · aging NCT05382286
Q2 2027
Sacituzumab govitecan-hziy (SG)
Triple Negative Breast Cancer
Estimated · fresh NCT05633654
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • BIKTARVY leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 115/161 completed
  • • Speed: 23 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges